MYC — TIMELINE

Reflecting on 25 years with MYC

Natalie Meyer and Linda Z. Penn

Abstract | Just over 25 years ago, *MYC*, the human homologue of a retroviral oncogene, was identified. Since that time, MYC research has been intense and the advances impressive. On reflection, it is astonishing how each incremental insight into MYC regulation and function has also had an impact on numerous biological disciplines, including our understanding of molecular oncogenesis in general. Here we chronicle the major advances in our understanding of MYC biology, and peer into the future of MYC research.

Research on MYC began at a time when the genetic basis of cancer was largely unknown. A quarter of a century has now passed since the human homologue of v-*gag–myc* was discovered (BOX 1). The lessons learned from studying the highly regulated and multifunctional MYC protein have proved instructive to researchers investigating a broad range of fields, including cell biology, cell cycle, apoptosis, development, signal transduction, transcriptional and post-transcriptional regulatory mechanisms, non-coding RNAs, stem cell biology and the molecular basis of cancer (FIG. 1). This Timeline will focus on MYC regulation and function directly pertaining to tumorigenesis. We have made a valiant attempt to highlight the many milestones in this journey, which is fully archived in over 19,000 published articles (TIMELINE).

Mechanisms of MYC deregulation

The oncogenic activation of MYC was initially perplexing. Other oncogenes identified at the time, such as HRAS, were versions of normal cellular genes activated by mutations in the coding sequence. These mutations were conspicuously absent in MYC[1]. Instead, three novel mechanisms of oncogenic activation were identified: insertional mutagenesis, chromosomal translocation and gene amplification (FIG. 2a). A major development within the past decade has been the realization that MYC deregulation is not restricted to gross genetic changes at the *MYC* locus. MYC can be deregulated by any one of several mechanisms that target its expression and/or activity either directly or indirectly (FIG. 2b). These new insights suggest that the impact of MYC deregulation on human cancer incidence is higher than previously thought, and is not restricted to translocations and amplifications of the *MYC* locus.

Insertional mutagenesis. Leukaemogenesis induced by the acutely transforming virus avian myelocytomatosis retrovirus (MC29) is due to retroviral transduction and generation of chimeric *v-gag–myc* (FIG. 2a). However, the neoplastic mechanism of the slowly transforming retroviruses was at first perplexing, and was finally unravelled through studies of avian leukosis virus (ALV). Analysis of DNA and RNA from ALV-induced tumours supported the supposition that viral integration into the host genome could inappropriately activate a nearby cellular oncogene (FIG. 2a). In 1981, B. Neel and colleagues demonstrated the existence of viral–cellular RNA chimaeras and showed that viral integration sites were evident at specific sites in the genome, yielding similar hybrid RNA molecules in independently infected birds[2]. Unlike the acutely transforming tumour viruses, the viral coding regions of their slowly transforming cousins were not involved and were often mutated and/or not transcribed[2,3]. Complementary DNA from five of the viral oncogenes that were known at the time, including *v-myc*, was hybridized to the avian lymphoma RNA, allowing identification of increased levels of *MYC* transcripts fused to proviral sequences in the tumours[4]. MYC was the first cellular oncogene that was shown to be activated through retroviral promoter insertion, and this hallmark observation was independently confirmed within the year[5]. A short time later, murine leukaemia proviral sequences were found adjacent to the *Myc* locus in mice and rats[6]. Taken together, these results implied that the researchers had uncovered a surprising reality: neoplastic transformation could result from the activation of a non-mutated cellular gene. On the basis of this pioneering work with *Myc*, insertional mutagenesis has been widely used as a tool to discover many cellular oncogenes[7] (FIG. 1).

Chromosomal translocation. Molecular analysis of mouse plasmacytomas revealed that the production of *Myc* mRNA resulted from a consistent recombination between the immunoglobin (Ig) heavy chain locus and the *Myc* oncogene[8,9]. Gross chromosomal translocations had been identified in human malignancies, but until human *MYC* was localized to chromosome 8 no direct biological role for these rearrangements had been assigned[10–12]. In Burkitt lymphoma, chromosomes 14, 2 or 22, which harbour the Ig heavy and light chain genes, are translocated with chromosome 8. The *MYC* locus was involved in these translocations, leading to the proposal that the juxtaposition of *MYC* to Ig loci was responsible for the lymphomas (FIG. 2a). In the same year, the oncogenic breakpoint cluster region (*BCR*)–*ABL1* fusion was mapped to the site of chromosomal translocation in the Philadelphia chromosome, but this abnormality generated a novel fusion protein[13]. In the case of *MYC*, overexpression of a non-mutated gene appeared to be adequate for tumour generation. Extensive analysis of the

Box 1 | **The discovery of retroviruses and MYC**

Researchers studying the molecular basis of cancer owe a great debt to P. Rous. In the early part of the 20th century, long before the molecular isolation of genetic material, he demonstrated that an entity causing cellular transformation could be transferred through cell-free filtrates. A retrovirus, now known as the Rous sarcoma virus (RSV), was shown to be the infective agent. The identification of reverse transcriptase in 1970 revealed the replication mechanism of retroviruses, and the purification of this enzyme provided an essential tool for the synthesis of DNA for use in hybridization studies. This enabled the isolation of the transforming sequences within RSV, as these were evident in the DNA of the infected cells. The gene responsible for the transforming potential of RSV was termed *src*. Using information gleaned from the isolation of *src*, the transforming sequence of the MC29 avian tumour virus was identified through hybridization studies and later named *myc*, for myelocytomatosis (the leukaemia caused by this virus). When the same gene sequences were identified in the DNA of non-infected cells, a theory developed: viral oncogenes were commonly captured from the normal cellular DNA. The detection of transforming sequences in tumour retroviruses revolutionized the study of molecular oncogenesis, leading to the identification of countless cellular oncogenes, as reviewed by H. Varmus[269].

Burkitt lymphoma and plasmacytoma translocation breakpoints, as well as the coding region of the activated allele, has advanced our understanding of MYC regulation. This chromosomal translocation was modelled by J. Adams and colleagues in the *Eμ–Myc* mouse, which develops a clonal lymphoma in the B-cell compartment[14]. Activation of human *MYC* as a result of chromosomal translocations is common in haematopoietic tumours[15].

Amplifications. Cancer cells contain many types of karyotypical abnormalities, including homogeneously staining regions and double-minute chromosomes. The manner by which these aberrations can drive cancerous growth was also determined through studying *MYC*. Examination of homogeneously staining regions and double-minutes in colon cancer cell lines and leukaemic HL60 cells revealed that these cells harbour multiple copies of *MYC*[16–18] (FIG. 2a). Amplification of a new Myc member, *MYCN*, (which is normally only expressed during development) was discovered in a panel of human neuroblastoma cell lines and tumour samples[19,20] and was quickly associated with poor patient prognosis[21,22]. With the identification of *MYCL1* (which is also expressed normally only during development), it became clear that a well-documented genetic abnormality evident in lung cancer is the deregulation of one of the three transforming members of the Myc family (MYC, MYCN and MYCL1)[23–25]. More recently, the use of genome-wide scanning strategies revealed that *MYCL1* is amplified in several types of cancer, including ovarian carcinoma[26]. In contrast to chromosomal translocations in haematopoietic cancers, activation of the *Myc* genes by amplification is commonly detected in solid human tumours.



Figure 1 | **The MYC tree of knowledge.** The lessons learned from MYC research branched out and helped to advance many fields.

Timeline | **MYC research and cancer**



APC, adenomatous polyposis coli; HLH, helix–loop–helix; LZ, leucine zipper; TRRAP, transactivation/transformation-associated protein.

The control of MYC expression

With the realization that the gross genetic abnormalities that activated *MYC* in cancer universally led to deregulated expression of the intact coding region, a series of new questions arose. What is the normal expression pattern of MYC? How is this expression controlled in non-transformed cells?

In the early 1980s, the function of MYC was investigated using antibodies directed against the gag portion of the MC29 v-gag–myc fusion protein. It was shown that v-myc is a nuclear protein that binds to double-stranded DNA[27,28]. S. Hann, while in R. Eisenman's laboratory, demonstrated nuclear localization for the endogenous human protein shortly thereafter[29]. In 1983, Kelly *et al.* established a direct link between mitogenic stimulation of quiescent cultured cells and a rapid induction of *MYC* mRNA. Maximal mRNA levels of this immediate early response gene were reached within 2 hours of mitogen treatment in the presence of cycloheximide, an inhibitor of protein synthesis[30]. The mRNA[31] and protein[32] demonstrated extremely short half-lives, and both were expressed at constant levels once cells were in the cell cycle[33,34]. The phosphorylation pattern of MYC was also described and, like expression, was invariant throughout the cell cycle[33]. Anti-proliferative signals were shown to trigger rapid downregulation in MYC expression[35–38]. Clearly, these data indicated that MYC expression, and presumably MYC activity, was tightly regulated in non-transformed cells and designed to respond quickly to proliferative cues from the extracellular milieu.

Two questions immediately arose: what are the agonists that regulate MYC expression and is the control at the transcriptional or post-transcriptional level? Insight into these issues seemed to be the key to understanding MYC function and so a flurry of research ensued. This period of intense discovery, competition and excitement was peppered with controversy. Many research groups produced convincing, high-quality data that argued for completely distinct mechanisms of regulation. Although these were hotly debated issues at the time, it is now clear that a multitude of signal transduction pathways and numerous regulatory mechanisms have evolved to keep MYC expression under tight control.

Transcriptional control and mRNA turnover. In the mid to late 1980s, MYC transcriptional regulation was a primary focus for many laboratories. The first order of business was to clone and compare *MYC* genomic DNA from a wide variety of species (reviewed in REFS 39,40). The gene was found to have unusual topography, with a large non-coding exon I, followed by coding exons II and III. Several minor TATA-less promoters were mapped as well as the two major, classical TATA-containing promoter start sites at the 5′ end of exon I[41,42]. Two polyadenylation sites were also identified, as were several unusual products of antisense transcription[43–45]. To understand how extracellular stimuli controlled *MYC* transcription, DNAse I hypersensitivity sites were mapped in association with transcription[43,46,47]. Finer mapping was conducted using several assays and distinct response elements and their regulators were slowly defined. However, deciphering the complex regulatory mechanisms of transcription initiation was more of a challenge than for other genes (for discussion, see REFS 39,48,49). In 1986, *MYC* was identified as the first eukaryotic cellular gene to be regulated by transcription elongation control[43,44,50,51], and an elongation block was shown to occur during cellular differentiation. Loss of this control mechanism is evident in cancer. The *MYC* promoter is a key convergence node for multiple signalling cascades that result in an impressive regulatory network (reviewed in REF. 52). The constitutive deregulation of MYC transcription can occur by both direct and indirect effectors, leading to cellular proliferation and transformation[53–59] (FIG. 2b). Study of the regulation of the *MYC* promoter continues to provide new insight into novel transcriptional control mechanisms[52,60].

Research into mRNA turnover was a top priority from the mid 1980s to the early 1990s. Transcription alone could not account for the enormous differential in mRNA expression following either proliferative or anti-proliferative stimuli[38,61]. Rapid *MYC* mRNA turnover was dissected first in *cis* then in *trans* using novel methodologies involving both cell-free systems and intact cells[62]. Two distinct and widely applicable mechanisms of mRNA decay were discovered. The first is a translation-independent mechanism, involving poly(A) tail shortening that is regulated by AU-rich sequences in the 3′ untranslated region[63,64]. The second is a translation-dependent mechanism that is regulated by a region



of mRNA corresponding to the carboxy-terminal domain of the protein, known as the coding region determinant[65]. Increased mRNA expression is evident in tumour cells. However, this was initially controversial: was this a cause or consequence of cellular transformation? Evidence that deregulation of *MYC* mRNA expression was able to drive cancer development was shown with transgenic mouse models[14,66]. The increase in *MYC* mRNA stability in human cancers can result from direct and indirect mechanisms (FIG. 2b).

Protein expression and regulation. The control of MYC expression was analysed in the mid to late 1980s. Although multiple open reading frames have been identified, two encode universally expressed proteins that migrate as p64 and p67 and arise from an AUG codon at the 5′ end of exon II and a CUG initiation codon at the 3′ end of exon I, respectively[40,67–69]. Phosphopeptide analysis revealed that specific serine and threonine residues of MYC were phosphorylated *in vivo* (reviewed in REF. 70). The two residues that have primarily been in centre stage over the last 15 years, Thr58 and Ser62, are important for transformation and regulate both MYC stability and activity[71,72]. On the basis of evidence from several groups, it is thought that proliferative stimuli activate specific kinases to phosphorylate Ser62 and increase MYC stability. Phospho-Ser62 can then serve as a platform for phosphorylation of Thr58 by glycogen synthase kinase 3, enabling the tumour suppressor FBW7 to bind and then recruit the SCF^{FBW7} complex to direct MYC ubiquitylation and proteasomal degradation. Levels of regulation additional to this core model have recently been proposed, suggesting several potential approaches for neoplastic intervention[73–75].

Additional mechanisms to regulate MYC expression have been described within the past decade, and include the discovery of a short form of MYC that arises from translation initiation at residue 100 (REF. 76), and cap-independent translation of *MYC*[77]. MYC stability is an area of much interest at this time and further insight into the role and regulation of the expression of the Myc protein(s) and its activity in transformation is likely to expand further in the coming years.

Oncogene cooperation

It was also through studies with MYC that the concept of oncogene cooperation was established. H. Land, when in the laboratory of R. Weinberg, greatly advanced our understanding of transformation by cellular oncogenes when they attempted to transform primary rat embryo fibroblasts instead of using established, immortal fibroblasts. In these cells, expression of oncogenically activated *EJ-RAS* (an oncogenic variant of *HRAS1*) did not cause transformation as it did in the immortal lines. When *EJ-RAS* was co-transfected with either *v-myc* or *Myc*, however, the cells formed foci *in vitro*. This was the first evidence that cooperativity between cellular oncogenes was required for cellular transformation[78]. These results, in combination with E. Ruley's work establishing that the adenovirus early gene *E1A* could also collaborate with activated T24 *HRAS*, supported the idea that multiple genetic changes might be required for tumours to develop[79]. Building on these findings was the demonstration of collaboration between the anti-apoptotic gene *BCL2* and *MYC* by Vaux in the Adams laboratory[80]. Numerous cooperation studies involving MYC later indicated that an often important function of cooperating mutations is the abrogation of the apoptosis that is induced by oncogenic MYC (see below). Cooperating mutations can decrease the latency of disease or alter the tumour spectrum, as was evident when Strasser *et al.* in the Cory laboratory crossed *Eμ–Myc* with *Eμ–Bcl2* mice[81]. The cooperation model has held true for tumour development in human cell systems as well[82].

How does MYC function?

Despite the enormous progress during the first decade of research in understanding the regulation and oncogenic potential of *MYC*, the function of this nuclear phosphoprotein remained unknown. MYC expression was associated with growth of the cell, and overexpression conferred a reduced dependence on serum for rapid proliferation of tissue culture cells[84]. Two popular models emerged: that MYC was directly regulating DNA replication or that MYC was functioning as a regulator of gene transcription. Support for the former came from an intriguing correlative observation in *Xenopus laevis* showing that maternal MYC was recruited to the nucleus during a period in early development that was transcriptionally silent and characterized by rapid replication[85]. Despite reports that MYC had an important role in replication, excitement was replaced by frustration when these initial results were difficult to reproduce[86]. Interestingly, recent publications have re-awakened serious interest in understanding the role of MYC in DNA



Figure 2 | **MYC deregulation.** Deregulation of MYC expression can occur by many mechanisms. **a** | Originally discovered as a consequence of retroviral transduction, the v-*gag-myc* gene enabled acutely transforming retroviruses to drive tumorigenesis. This led to the discovery that deregulation could also occur as a consequence of gross genetic abnormalities that affect the *MYC* locus, including retroviral promoter or enhancer insertion, chromosomal translocation and gene amplification. **b** | More recently, it has become clear that MYC can be deregulated by many additional mechanisms, including activation of hormones or growth factors, their receptors, second messengers or transcriptional effectors that converge on MYC expression. Alterations in mechanisms that directly or indirectly stabilize *MYC* mRNA and/or protein can also deregulate expression of this potent oncogene.

replication[87–89]. However, in the late 1980s further studies on replication were quickly overshadowed by strong evidence that MYC could function as a regulator of gene transcription (reviewed in REFS 39,90).

MYC as a transcriptional activator. In the mid 1980s it was shown that ectopic MYC expression could modulate promoters linked to indicator genes[91], but it was the characterization of two important domains that revealed the sequence-specific DNA binding and transcriptional activity of MYC. S. McNight's group noticed sequence similarities between several known DNA-binding proteins, including MYC, and through molecular modelling hypothesized the existence of the leucine zipper (LZ) domain[92]. Shortly thereafter, a helix–loop–helix (HLH) domain was identified within MYC[93] (BOX 2). These regions were essential for transformation[94,95]. C. Dang's group then showed direct transcriptional activity of MYC by fusing the amino-terminal domain of MYC, including the MYC homology box II (MBII) region that is crucial for cellular transformation, to the DNA binding domain of the yeast GAL4 protein[96]. Building on these studies, and what had been learned from other basic HLH (bHLH) and bLZ proteins, DNA binding by MYC was observed at last[97,98]. In 1991, E. Blackwood and R. Eisenman provided another crucial missing link. They identified the MYC partner protein MAX and showed that MYC–MAX heterodimers bound a CACGTG E-box sequence with high affinity[99]. Using a series of elegant MYC- and MAX-interdependent binding mutants, B. Amati and colleagues in the Land laboratory showed that MYC–MAX heterodimerization is essential for MYC transformation[100]. Although MYC appears to be dedicated to MAX, MAX binds to members of the Mxd family through the HLH–LZ region[101] and these interactions provide yet another mechanism to functionally regulate MYC activity (recently reviewed in REFS 102–105). The MYC–MAX complex can activate gene transcription by several mechanisms. S. McMahon, while in the laboratory of M. Cole, identified TRRAP (transactivation/transformation-associated protein) as an MBII binding protein that was essential for the transformation activity of MYC[106]. They subsequently demonstrated that, through TRRAP, MYC recruits histone acetylation complexes to chromatin, including the GCN5-containing SAGA complex[107]. Accumulating evidence suggests that MYC also regulates chromatin structure through its interaction with other protein partners including INI1 (also known as hSnf5), which is part of the SWI–SNF ATP-dependent chromatin remodelling complex[108]. This is consistent with a recent study by Knoepfler *et al.* in the Eisenman laboratory showing that loss of MYCN expression results in widespread changes in histone methylation and acetylation, leading to chromatin inactivation, which again is functionally linked to GCN5 (REF. 109). Eberhardy and colleagues in the Farnham laboratory showed that MYC can also increase transcription following the recruitment of RNA polymerase II by promoting elongation through the PTEFb (positive transcription elongation factor) complex[110,111]. New evidence from Cowling and Cole suggests that MYC can also promote RNA polymerase II C-terminal domain phosphorylation and mRNA cap methylation[112]. Clearly the role of MYC as a positive regulator of gene expression is well-established, mechanistically diverse and important for transformation (reviewed in REFS 113–115).

MYC as a transcriptional repressor. One of the first indicators that MYC might also function as a transcriptional repressor came from studies published in the 1980s that suggested that MYC participates in a negative feedback loop. For example, several groups observed that the non-translocated, normal *MYC* allele in Burkitt lymphoma was not expressed. In 1988, it was shown that the product of the *v-myc* gene was able to downregulate endogenous *MYC*[116]. Soon

after, ectopic MYC was shown to suppress transcriptional initiation of endogenous *MYC* in a dose-dependent manner[117]. Structure–function analysis demonstrated that the regions of MYC required for transformation[95] were also required for negative autoregulation[118]. Moreover, loss of autosuppression was associated with more aggressively transformed cells[119]. The idea emerged that MYC repression of target gene transcription might also contribute to transformation. Despite further support for this provocative association[120,121], knowledge of the molecular mechanism of MYC as a repressor lagged behind that of MYC as a transactivator. Insight emerged when the Ziff laboratory showed that MYC could repress promoter activity by a mechanism that was uncoupled from E-box MYC binding sites and dependent upon initiator elements in the basal promoter region[122]. The MBII and the bHLH–LZ regions were also essential for this repression.

Understanding of MYC repression was significantly advanced with the identification of bona fide repressed gene targets and the MYC-binding proteins that are required for repression. The present mechanistic model is that MYC–MAX complexes interact[123] with transcriptional activators that are bound directly to DNA through enhancer or initiator elements, including nuclear factor Y (NFY), SP1 and MYC-interacting zinc finger 1 (MIZ1)[124]. These multi-protein complexes are thought to displace co-activators and recruit co-repressors[125,126]. Genome-wide analyses demonstrate that MYC represses at least as many targets as it activates, further emphasizing the role of repression in MYC function, including transformation.

Identifying MYC target genes

One gene at a time. Ten years after the identification of human MYC, its first transcriptional target was identified. A successful strategy developed by M. Eilers while in M. Bishop's laboratory involved the fusion of human *MYC* to the hormone-binding domain of the oestrogen receptor (*ER*), resulting in the conditional, rapidly regulatable MYC–ER fusion protein[127]. MYC–ER activation could drive quiescent cells to enter and progress through the cell cycle[127], and activation of MYC–ER in the presence of cycloheximide identified α-prothymosin (*PTMA*) as a transcriptional target of MYC[128]. Additional MYC target genes, including ornithine decarboxylase 1 (*ODC1*)[129,130], were identified with this approach. Modifications to the hormone-binding domain by Littlewood *et al.* in the Evan laboratory created MYC–ER^{TAM}, which is responsive to 4-hydroxytamoxifen only, allowing *in vivo* use[131]. More than 15 years later, the *MYC–ER^{TAM}* allele is still widely used, and this conditional fusion hormone strategy has been used to regulate a number of other proteins in a wide variety of cell types and mouse models[132].

Another strategy to delineate direct targets exploited the MYC-null rat fibroblast cell system that was developed by J. Sedivy[133] and evaluated whether regulation of expression was dependent on MYC during mitogen-stimulated cell cycle entry[134]. This approach further supported evidence that *GADD45A* and *CAD* were direct targets of MYC repression and activation, respectively[135,136]. Combining both the cycloheximide and MYC-null cell approach certainly distinguished bona fide MYC targets, but this was a slow and labour-intensive screening process[137].

Large-scale analysis. With the new millennium came expression microarrays, providing an opportunity to conduct large-scale analyses of MYC-regulated genes. However, the resulting gene lists showed little overlap between studies. Perhaps one of the greatest challenges that researchers face with MYC is that changes of the mRNA expression levels of MYC-regulated genes are relatively small, exacerbating the poor signal-to-noise ratio that was associated with early expression array analyses[138]. Several criteria for distinguishing true transcriptional targets were delineated[56],

Box 2 | **Regions of human MYC and their roles in transformation**



MYC homology box is a region that is highly conserved between MYC, MYCN and MYCL1, unless otherwise stated[95,113].

Transactivation domain (TAD; amino acids (aa) 1–143)
The TAD can confer activation of gene transcription to a heterologous DNA-binding domain.

MYC homology box I (aa 44–63)
This domain is essential for primary REF co-transformation with activated Ras. Deletion mutants are able to transform Rat-1A cells. Within this region MYC is highly regulated through phosphorylation of Thr58 and Ser62.

MYC homology box II (aa 128–143)
This domain is essential for transformation of REFs and Rat-1A cells, important for transcriptional repression and activation, region of interaction with TRRAP (transactivation/transformation-associated protein) and other cofactors involved in transformation.

MYC homology box IIIa (aa 188–199)
This domain is conserved in MYC and MYCN but not in MYCL1. It is essential for Rat-1A transformation, and shows intermediate transforming potential compared with the activity of the wild type and of an MBII deletion mutant *in vivo*.

MYC homology box IIIb (aa 259–270)
This domain is conserved, but no specific function has yet been assigned to it.

MYC homology box IV (aa 304–324)
This domain is required for focus formation of Rat-1A and RK3E cells. It is dispensable for REF co-transformation focus and Rat-1A soft agar assays.

Primary nuclear localization signal (NLS; aa 320–328)
Subcellular localization to the nucleus is encoded primarily by this region.

Basic region (BR; aa 355–369)
This region is essential for full transformation of primary and immortal cells, and is responsible for specific binding of canonical and non-canonical MYC E-boxes to DNA, with MAX.

Helix–loop–helix–leucine zipper (HLH–LZ; aa 370–439)
This domain is essential for full transformation of primary and immortal cells, and is responsible for interaction with MAX.

Table 1 | **MYC-regulated activities and gene targets associated with transformation**

Functional class	Description of function	Examples of responsible genes*
Cell cycle	MYC–ER activation drives quiescent cells to enter and transit through the cell cycle; primary cells from conditional knockout mice arrest in the absence of MYC expression	Cyclin D2, CDK4 (induced); p21, p15, GADD45 (repressed)
Differentiation	Deregulated MYC blocks differentiation of many cell systems; MYC accelerates epidermal differentiation	CEBP (repressed)
Cell growth, metabolism and protein synthesis	MYC expression levels are associated with body size owing to regulation of cell size and cell number	Lactate dehydrogenase, CAD, ODC, ribosomal proteins, EIF4E, EIF2A (induced)
Cell adhesion and migration	MYC drives tumorigenesis in part by allowing for anchorage-independent growth	N-cadherin, integrins (both repressed)
Angiogenesis	MYC induces angiogenesis in a wide range of tissues	IL1β, miR-17–92 microRNA cluster (induced), thrombospondin (repressed)
ROS, DNA breaks and chromosomal instability	MYC can contribute to instability, trigger telomere aggregation and increase ROS production	MAD2, TOP1, BUBR1, cyclin B1, MT-MCI
Stem cell self-renewal and/or differentiation	Ectopic MYC can potentiate induced pluripotent stem cells; MYC can control the balance between stem cell self-renewal and differentiation	To be determined, potentially genes associated with cell cycle, immortalization, adhesion and migration
Transformation	MYC can drive focus formation and anchorage-indepenent growth *in vitro* and full tumorigenesis *in vivo*; MYC is often deregulated in primary human cancers	Multiple targets are thought to contribute to transformation

This information is adapted from Dang[138]. *For further information see MYC Cancer Gene. CDK, cyclin-dependent kinase; CEBP, CCAAT/enhancer-binding protein; EIF, eukaryotic translation initiation factor; ER, oestrogen receptor; IL1β, interleukin 1β; MT-MCI, MYC target in myeloid cells 1; ROS, reactive oxygen species; TOP1, topoisomerase 1.

and a database (MYC Cancer Gene) was developed by C. Dang to manage and categorize MYC-regulated genes according to these criteria[139].

In recent years, the chromatin immunoprecipitation assay (ChIP) has allowed researchers to better identify true direct targets of MYC. Thanks to this technology we now know that MYC binding to genomic loci is highly dependent on chromatin structure and modification, such as CpG and/or histone methylation[140,141]. Combining the sensitivity and specificity of ChIP with high-throughput array technology (ChIP-chip), or with high-throughput nucleotide sequencing (ChIP-PET and ChIP-seq) further advanced the field[142–145]. For the first time, the entire genetic programme of MYC target genes could be visualized. By integrating these data with the complementary expression array data, MYC-directed pathways can be distinguished.

Experiments performed with these new assays suggest that MYC is a global transcriptional regulator. Unlike other transcription factors, MYC can bind to approximately 10–15% of the genome and can regulate both genes encoding proteins and those encoding non-coding RNA products of several functional classes[138,143]. A common feature among these many arrays is the plethora of genes that regulate the cell cycle and metabolism, including genes that encode ribosomal proteins as well as RNA binding and processing factors, which is consistent with the ability of MYC to regulate transcription mediated by all three RNA polymerases[146–150]. Much excitement has been generated recently about the role of non-coding, regulatory RNAs, and MYC research is at the forefront of these studies as well (FIG. 1). The first oncogenic microRNA polycistron was shown to be regulated by MYC[151,152]. The fields of tumorigenesis, epigenetics and non-coding RNA collided in a report demonstrating allele-specific, oncogenic upregulation of *H19* by MYC[140]. For full coverage of MYC target genes we refer the reader to several in-depth review articles[113,124,153,154].

How does MYC transform cells?

In parallel with the hunt to identify MYC target genes and their mechanisms of regulation, there was an equally voracious appetite to identify and understand the main biological activity and pathway controlled by this potent oncogene. The successful MYC researcher who cracked the case would be heralded for providing a major molecular advance in our understanding of cancer aetiology: the race was on. Little did we know that MYC would be multifunctional and achieve its notoriety as a potent oncogene by regulating many pathways that collectively contribute to neoplasia. A brief overview of the numerous proliferative activities directed by MYC is provided, along with examples of the genes responsible[138], in TABLE 1.

Cell cycle and differentiation. It was clear from the start that MYC had a unique and crucial role in cell proliferation. In cells with activated MYC, G1 is often shortened as cells enter the cell cycle, and MYC is essential for G0/G1 to S phase progression[57,70,155,156]. Work from many groups over the past 15 years has revealed the mechanisms of cell cycle regulation by MYC[56,157]. For example, MYC abrogates the transcription of cell cycle checkpoint genes (for example, *GADD45* and *GADD153*) and inhibits the function of cyclin-dependent kinase (CDK) inhibitors, either through direct repression of gene transcription or indirectly through degradation or sequestration. MYC also promotes cell cycle progression by activation of cyclin D1, cyclin D2, cyclin E1 and cyclin A2, as well as CDK4, cell division cycle 25A (CDC25A), E2F1 and E2F2. This example further reinforces the notion that multiple pathways are regulated by MYC in order to drive any one biological programme.

Although ectopic MYC expression can dramatically block the differentiation of many different cells types, MYC can also stimulate cellular differentiation[158–162]. Several groups have demonstrated that MYC downregulation is required for cells to exit the cell cycle and undergo differentiation. This important point of regulation is further enforced by the induction and function of the Mxd family members in response to differentiation cues[102–105,163–167]. MYC is now well-established as a regulator of differentiation and more recently has been

shown to modulate cell fate. The role of MYC expression during normal development is associated with proliferative expansion and cellular migration. Loss of MYC expression in specific cellular compartments leads to striking phenotypes[168–171]. The relevance to tumorigenesis is intuitive, with deregulated MYC preventing differentiation and promoting migration, leading to the features of aggressive, less differentiated, metastatic cancers.

Cell growth, genomic instability and angiogenesis. In the second half of the 1990s MYC was hailed as having three new talents that promote tumorigenesis: regulating cell size, altering genomic stability and triggering the angiogenic switch. The ability of MYC to promote cell growth (causing cells to double in mass and size) was shown in normal and tumour cells, both *in vitro* and *in vivo* (described below). MYC enables cell growth by providing the cell with an abundant supply of several classes of basic building blocks as well as increasing cell metabolism and protein synthesis[172,173]. When MYC is activated, cellular growth is no longer rate-limiting to the proliferative process. Several MYC target genes are thought to have a role in this activity, including those associated with cellular metabolism, ribosomal and mitochondrial biogenesis, and protein and nucleic acid synthesis. Interestingly, microarray analyses show that these are universal targets, commonly regulated by MYC in a wide variety of cell types[138,174,175].

The second reported skill of MYC was initially described by S. Mai and colleagues, who showed that specific gene amplification occurred at a high frequency in cells with deregulated MYC[176,177]. Additional research shows that MYC can promote chromosomal instability[178–180]. However, because the processes appear to be highly context-dependent, the role of MYC in genomic instability has been a subject of debate and controversy[181–184]. Several mechanisms have been proposed, including increased levels of reactive oxygen species, alterations in chromosome structure[181,185], overcoming the p53 checkpoint[180,186,187], and induction of a DNA damage response and/or replication[89,188–190]. Losing the high-fidelity organization of the genome is a hallmark of tumorigenesis that can clearly be associated with MYC deregulation.

The ability of MYC to promote the angiogenic switch is a non-cell-autonomous activity that was also uncovered in the late 1990s. A. Thomas-Tikhonenko introduced Rat-1A cells *in vivo* as xenografts and showed angiogenesis that was associated with MYC deregulation[191]. Downregulation of thrombospondin is vital to angiogenesis and is potentially achieved through MYC induction of the miR17–92 microRNA cluster[192,193]. S. Pelengaris and G. Evan have shown that, in pancreatic islet cells, increased MYC expression and release of interleukin 1β (IL1β) is crucial for the initiation of angiogenesis[194,195]. More recently, L. Soucek and colleagues have shown that the recruitment and degranulation of mast cells is essential for the subsequent maintenance of angiogenesis during tumour expansion[196,197]. It will be interesting to learn whether new insights into the role of MYC in regulating normal vascular development and inflammation also play a part in tumorigenesis.

Role in apoptosis

The role of MYC in cellular transformation and proliferation was already well-established when a remarkable observation involving MYC was reported in the early 1990s: ectopic expression of the protein sensitized cells to undergo apoptosis[198–200]. In the absence of specific survival factors, deregulated MYC expression invoked a default pathway of cell death[200,201]. Again, observations that were first made while studying MYC were relevant for other oncogenes (FIG. 1), including *E2F1* and *E1A* (reviewed in REF. 202). Researchers now had an explanation for the clonal nature of MYC tumours and the cooperation observed between MYC and BCL2 (REFS 81,203,204). Deregulated MYC alone promoted a hyperproliferative state, which was kept in check by a concomitant increase in cell death. Abrogation of MYC-potentiated apoptosis is crucial for cellular transformation and, once this occurs, clonal tumours can result. The crucial role of MYC in apoptosis has been supported by work in *Myc*-null cells: in the absence of *Myc*, cells are resistant to diverse apoptotic stimuli[205,206]. The precise molecular mechanisms of how MYC induces apoptosis remain unclear; however, once again it appears that multiple pathways are regulated by MYC to potentiate this biological activity (recently reviewed in REFS 202,207,208).

In 1994, the Eick and Hay laboratories provided evidence that MYC deregulation activates the tumour suppressor p53 and triggers apoptosis[209,210]. Zindy and colleagues in the Roussel laboratory showed mechanistically that deregulated MYC upregulates ARF, which in turn activates p53 to regulate a cohort of target genes involved in apoptosis and growth arrest[211]. MYC directs the latter by repressing the expression of the CDK inhibitor p21 through interaction with the transactivator MIZ1 (REFS 212–215). Interestingly, MYC-induced apoptosis is not always dependent upon MIZ1 interaction[212], which demonstrates that multiple pathways are regulated by MYC to potentiate apoptosis. The importance of the ARF–MDM2–p53 pathway in MYC-induced apoptosis is highlighted by the accelerated tumorigenesis evident with the loss of these tumour suppressors in mouse models of MYC oncogenesis[216–222]. The interplay between this pathway and MYC activity continues to be instructive for understanding MYC and cancer. For example, evidence from the Hann laboratory shows that ARF and MYC can partner to selectively control MYC as a transcriptional regulator, leading to apoptosis[186]. Moreover, functional cloning has identified additional oncogenic regulators of the ARF–MDM2–p53 axis, such as BMI1, TWIST1 and CUL7, which can cooperate with MYC in human disease[223–225].

MYC can also sensitize cells to undergo apoptosis by altering the balance of pro- and anti-apoptotic factors, priming the cells for

Box 3 | **MYC messages from the fruit fly**

The diminutive fruit fly is a result of mutation in the gene encoding the *MYC* orthologue, *dm*, and Laura Johnston and Peter Gallant — while in the Edgar and Eisenman laboratories — showed that dMyc controls cell growth at the level of cell size[270]. A. Trumpp, while in M. Bishop's laboratory, showed that decreased *Myc* expression also leads to a small mouse, but the mouse has a reduced number of cells, rather than smaller cells[156]. A potential common mechanism for the ability of MYC to control body size was highlighted by genome-wide analysis of dMyc binding[271]. Like mammalian MYC, dMyc binds to a large number of sites in the genome and controls the transcription of many genes including key regulators of ribosome biogenesis, which are essential for cell growth. Another feature of the dMyc and dMax flies that appears consistent with mammalian MYC is an intact autosuppression mechanism[272]. Moreover, another dMax interactor, dMnt, the orthologue of mammalian MNT, has recently been identified[239,273]. In a recent genetic screen, R. Eisenman's group has identified a novel dMyc-binding protein, the Trithorax group protein Little imaginal discs (Lid), as being functionally involved in dMyc-induced cell growth, and this interaction is intact in mammalian cells[274]. In addition, a recent novel and unexpected discovery from *D. melanogaster* research is the ability of dMyc to regulate cell competition in a dose-dependent manner[275,276].

Table 2 | **Representative mouse models used to study Myc function**

Model	Strategy	Tumours	Refs
Transgenic models			
MMTV–MYC	MYC expression under the control of the hormone-responsive MMTV promoter	Mammary adenocarcinoma developing after first pregnancy	291
WAP–MYC	MYC expression under the control of the mammary-specific, hormone-responsive WAP	Mammary adenocarcinoma, expression in tumour material becomes independent of hormone stimulation	292
Eμ–MYC	MYC expression under the control of the immunoglobulin enhancer	Clonal B-cell lymphoma	14
Myc-null models			
Myc-null	Homologous recombination to eliminate *Myc* expression	Embryonic lethal	241
Conditional *Myc*-null	Uses the Cre–*loxP* system to allow for targeted recombination of *Myc* allele	Used to study the role of *Myc* in tumorigenesis and normal tissue development	155,156
Inducible transgenic models			
tTA Tet-*O*-MYC	Ectopic MYC expression in the absence of tetracycline	Regulatable tumours in T cells, B cells, liver and bone	248
rtTA Tet-*O*-MYC	Ectopic MYC expression in the presence of tetracycline	Regulatable tumours in breast	252,253
MYC–ER^{TAM}	Ectopic MYC activity in the presence of TAM	Regulatable tumours in skin and pancreatic islet cells	194,195,293

ER, oestrogen receptor; MMTV, mouse mammary tumour virus; rtTA, tetracycline-on transactivator; TAM, 4-hydroxytamoxifen; tTA, tetracycline-off transactivator; WAP, whey acidic protein.

death when conditions are appropriate. In the *Eμ–Myc* model of lymphomagenesis, the Cleveland laboratory showed that MYC indirectly suppresses the anti-apoptotic proteins BCL2 and BCL-X_L[226–228]. This is consistent with evidence showing that MYC triggers apoptosis through BAX[229,230] and that MYC protein expression is crucial for the conformational change that activates the pro-apoptotic protein BAX[205,231]. In this way, MYC activity directly influences cytochrome *c* release from the mitochondria, and therefore the activation of downstream effector caspases. Indeed, Eischen *et al.* showed that loss of BAX impairs potentiation of apoptosis by MYC *in vivo*[232]. The Prendergast laboratory showed that MYC sensitizes cells to undergo apoptosis by both p53-dependent and p53-independent mechanisms[233]. The latter is shown by the indirect upregulation of the pro-apoptotic BIM molecule. This was triggered by the observation by the Cory laboratory that *Eμ–Myc*;*Bim*-null or *Eμ–Myc*; *Bim*-haploinsufficient animals quickly developed lymphomas without inactivating the p53 tumour suppressor pathway[234]. Interestingly, the Lowe laboratory engineered mice to express MYC mutants that are evident both in Burkitt lymphoma and in *v-myc* isolates that are known to have reduced apoptotic potential, and these animals succumbed earlier to lymphoma. These mutants were unable to upregulate expression of *Bim* (also known as *Bcl2l11*)[235]. Many elegant experiments clearly show that MYC can sensitize cells to undergo apoptosis and that suppression of this activity is vital to tumorigenesis. By elucidating the pathways through which MYC drives apoptosis, we imagine that the MYC-deregulated tumour could be forced to self-destruct by resurrecting these abrogated pathways, as was recently demonstrated by Goga *et al.* in the Bishop laboratory[202,236].

Insights from model organisms

Use of the fly as a model organism to study MYC function became a serious focus of attention about 10 years ago when *Drosophila melanogaster dMyc* and *dMax* were cloned and shown to bind as a complex to the canonical CACGTG E-box sequence[237,238] (BOX 3). Given that the MYC–MAX–Mxd network has been shown to be conserved in flies, one would predict that this model will continue to surprise and advance our understanding of this multi-talented protein in both invertebrates and vertebrates[154,239,240].

The common house mouse, *Mus musculus*, has been invaluable in revealing the effects of altering MYC expression on both development and disease. In the interest of space, only a limited number of insights can be highlighted (TABLE 2). In 1993, a crucial requirement for MYC was established when *Myc*-null mice failed to develop beyond embryonic day 9.5 (REF. 241). *Mycn* knockout was similarly lethal at embryonic day 10.5, whereas, curiously, *Mycl1*-null mice are viable[163]. In 2001, two independent groups reported the generation of conditional *Myc*-null mice using Cre–*loxP* technology[155,156]. Initial fibroblast and haematopoietic cell studies re-affirmed an absolutely critical role for MYC in the cell cycle. Conditional knockout mice of MYC and MYCN are now being used to identify the precise role of Myc in both tumour and normal tissue, including the recently identified role of Myc in regulating stem cell self-renewal and differentiation[109,168,171,242–247].

Several transgenic animals have been developed to elucidate the mechanism whereby deregulated MYC contributes to tumorigenesis (TABLE 2). In 1999, new mouse models were developed that used two mechanisms to temporally control the expression or activity of MYC. Felsher and Bishop used the Tet-on and Tet-off systems to allow ectopic *Myc* expression to be regulated by the presence and absence of tetracycline, respectively, whereas the MYC–ER^{TAM} system of the Evan laboratory allows ectopic MYC to function in the nucleus only after treatment with 4-hydroxytamoxifen[195,248]. In these experiments, deregulated MYC expression is used to drive tumour growth in specific cell types and then MYC expression is turned off, allowing researchers to observe the consequences of MYC inactivation. In all of the regulatable models tested so far (TABLE 2), inactivation of MYC is sufficient to cause regression of the tumours, through pathways that appear to be specific to the cell type and tumour[249,250]. For instance, in transplanted tetracycline-responsive osteosarcoma tumours, inactivation

of MYC resulted in the regression of tumours and differentiation into mature bone. Following differentiation, reactivation of the MYC allele did not lead to new tumours; instead, the MYC-expressing cells were eliminated through apoptosis[251]. By contrast, inactivation of MYC in mammary epithelial tumours caused initial regression, but neoplastic properties were quickly re-established upon reactivation of MYC. Some tumours even escaped dependence on MYC and returned without reactivation[252,253]. Interestingly, in pancreatic islet cells, researchers were unable to establish tumours upon MYC–ER^{TAM} activation without co-expression of anti-apoptotic BCL-X_L or the loss of tumour suppressors ARF or p53 (REF. 216). Inactivation of MYC again led to regression, and reactivation in this genetic context led to rapid tumour restoration[194]. These studies and others will hopefully determine the conditions under which we might expect cancer patients to benefit from therapeutic targeting of MYC, and those instances in which this approach may not be beneficial or may be optimally used in combination therapy[254,255].

Future directions

This Timeline provides an opportunity not only to reflect on and chronicle the journey of the last 25 years of MYC research, but also to critically evaluate where we are now, be informed by how we got here, and decide the next steps. Where are the immediate gaps and opportunities? Two major areas as well as several additional outstanding and important questions are briefly highlighted. For further insight and discussion, please see the Luscher and Larsson summary of a recent MYC conference[256] and the articles edited by Cole and Henriksson[257].

Exploiting MYC to improve patient care at the level of customized diagnosis and treatment is essential. We now have the technology to develop a diagnostic tool to score oncogenic MYC on the basis of activity as a transcription factor, independently of the multiple mechanisms of MYC deregulation. Certainly, the recent recognition of MYC-associated genetic fingerprints in primary human tumours is an exciting development[258–260], although further testing and validation is required. This line of exploration will also advance fundamental research and address whether MYC controls the self-renewal potential of tumour-initiating cells of certain cell-types (BOX 4). Is it this feature that distinguishes MYC as such an aggressive oncogene? The large fraction of human cancers harbouring deregulated MYC makes it an attractive candidate for targeted therapy. Whereas MYC research was often pioneering in advancing our understanding of gene regulation and function, targeting MYC as an approach in the fight against cancer has lagged behind. Further understanding of MYC structure would strongly support efforts in drug design. A number of anti-MYC therapeutic strategies are currently being investigated, and have been recently reviewed[261–266]. A breakthrough in the development of an effective MYC therapeutic could mark a key advance in cancer treatment.

MYC is often described as functioning in a context-dependent manner, yet this remains ill-defined at a molecular level. MYC is downstream of many signal transduction pathways, functioning as a central hub that integrates multiple intracellular and extracellular cues. MYC then processes and interprets these instructions, much like the central processing unit of a computer. Such a network manager is essential in higher organisms, which might explain why MYC is not evident in worms and yeast. We envision this central processing unit function at a molecular level as the regulation of post-translational modifications, which then alter MYC activity through any number of changes, including expression, stability, cofactor binding and DNA occupancy. MYC may bind to many sites in the genome to remain nimble and orchestrate the genetic programme that is dictated by signalling. The number of MYC molecules per cell is also influential, as MYC function is often dose-dependent. Evidence from B. Amati's group suggests that DNA binding site occupancy is based on relative affinity, histone marks and chromatin configuration[141,267]. Clearly, all signalling is significantly determined by the type and transformation state of the cell[53,150,268]. Understanding signal integration and outcome, as it relates to MYC regulation and function, remains a challenge that needs attention. Embedded in this task is the incorporation of the many feedback and feed-forward pathways in which MYC participates.

Answers to several additional discrete questions regarding the mechanism of MYC action remain a focus of future research endeavours (BOX 5).

This journey of discovery has shown that MYC is like no other oncoprotein — always full of surprises and rarely conforming to the expected models. Clearly with MYC research it is important to think outside the box, design well-controlled experiments, and let the data guide the interpretation of results and the design of next steps. Stay observant and do not shy away from bizarre, unexpected results; they are probably real.

Summary

A friend and colleague, J. Woodgett, recently jested that MYC researchers would probably never be unemployed. MYC has been, and still is, a challenging yet fascinating study. Many new insights into the regulation and function of MYC have pushed the boundaries of our understanding of the fundamental mechanisms of normal and neoplastic cell growth, death and development. The next phase of MYC research promises to be as challenging and rewarding as the first 25 years.

Box 4 | Stemness and self-renewal potential

The newest addition to MYC's already illustrious list of abilities is regulation of cell 'stemness'[277]. Through conditional knockout mouse analysis, the Trumpp and Eisenman laboratories have shown that *MYC* and *MYCN* were essential in the normal developmental control of haematopoietic and neuronal stem cells, respectively[168,171]. Mouse embryonic stem cells are dependent on leukaemia inhibitory factor (LIF) for maintenance and the Dalton laboratory showed that MYC is essential and can functionally substitute for this activated signalling pathway[278]. In 2007, MYC was one of four genes in a cocktail that was shown to re-programme pluripotency in a normal terminally differentiated primary fibroblasts to generate an induced pluripotent stem cell (iPS)[279,280]. Thankfully for the purposes of regenerative medicine, MYC is dispensable for iPS development[281]. However, the implications of this novel stemness function of MYC in the context of controlling the putative tumour stem cell cannot be ignored[277]. Evidence from several mouse models, including the Felsher model of MYC transformation of hepatocellular cancer[283], supports the notion that MYC deregulation has an important role in the initiation and maintenance of the tumour stem cell. It is intriguing that the tumour stem cell signature is evident in tumours that are undifferentiated and aggressive — molecular and phenotypical features that are reminiscent of MYC-activated tumours[83,144,260,284–286]. Further links between stemness and MYC emerge with every update of PubMed. For example, S. McMahon recently showed that a novel member of the stem cell signature, USP22, is a co-activator that is essential for MYC transformation[287]. Clearly this field is in its infancy, but it promises to determine whether the frequently poor prognosis of MYC-activated tumours is due to MYC enabling the expansion and maintenance of the tumour-initiating cell.

Box 5 | **Key unanswered questions**

- Are there transformation-associated mutations in MYC that have not yet been identified? With high-throughput sequencing of whole genomes of normal and tumour cells, this interesting question will soon be answered. Similarly, do MYC-associated single nucleotide polymorphisms have a role in cancer development and, if so, how?
- Does MYC binding to chromatin serve transcription-independent functions, including the regulation of chromosomal integrity, gene expression, chromatin structure, cellular replication and genomic instability? Prompted by several recent reports, these lines of investigation require further attention.
- To learn how MYC is able to distinguish itself as such a universal and aggressive oncogene, a vital next step is to functionally discriminate the genes, pathways and biological activities that MYC controls to drive transformation. To distinguish which are functionally crucial, approaches that are likely to be fruitful include high-throughput or gene-specific small interfering RNA screens.
- As a regulator of gene transcription, how is it determined when MYC will function as a transcriptional activator or repressor? How are the many mechanisms of MYC regulation of gene expression integrated or coordinated at any given target? Which targets are regulated by MYC alone and which are dependent on MYC in conjunction with a cooperating transcription factors?
- Are there MAX-independent functions of MYC? Are there functions for MYC outside of the nucleus?
- How does MYC direct cell competition and is this important in cancer?
- How is MYC regulated in the stem cell and how does MYC regulate stem cell fate?
- Given the incredible selective pressure to block MYC-potentiated apoptosis in the tumorigenic process, it seems logical that many more mutations exist to affect this important cooperating event. These will probably be cloned using functional cloning strategies. Similarly are there cooperating mutations that overcome the MYC-induced DNA damage response?
- MYCN and MYC are interchangeable for development[288], but are they functionally equivalent in transformation? Why is MYCL1 so different?
- Given that so many viruses harness MYC to promote their own life cycle (for examples see REFS 289,290), it is likely that the cancer cell has devised similar mechanisms to exploit and deregulate MYC protein for further expansion. Viruses have always been a rich resource for understanding oncogenesis. What additional lessons can be learned?
- Is MYC stability altered at specific subcellular locales, or when in partnership with certain DNA, RNA or protein molecules, or as a mechanism to regulate function, or in response to becoming decorated with one or more post-translational modifications?

Natalie Meyer is at Amgen Canada, Inc. Mississauga, Ontario, L5N 7Y2, Canada.

Linda Z. Penn is at the Division of Cancer Genomics and Proteomics, Ontario Cancer Institute, 610 University Avenue, Room 9-628, Toronto, Ontario M5G 2M9, Canada.
Correspondence to L.Z.P.
e-mail: lpenn@uhnresearch.ca

doi:10.1038/nrc2231

1. Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. *Nature Rev. Cancer* **3**, 459–465 (2003).
2. Neel, B. G., Hayward, W. S., Robinson, H. L., Fang, J. & Astrin, S. M. Avian leukosis virus-induced tumors have common proviral integration sites and synthesize discrete new RNAs: oncogenesis by promoter insertion. *Cell* **23**, 323–334 (1981).
3. Payne, G. S. *et al.* Analysis of avian leukosis virus DNA and RNA in bursal tumours: viral gene expression is not required for maintenance of the tumor state. *Cell* **23**, 311–322 (1981).
4. Hayward, W. S., Neel, B. G. & Astrin, S. M. Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis. *Nature* **290**, 475–480 (1981).
5. Payne, G. S., Bishop, J. M. & Varmus, H. E. Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas. *Nature* **295**, 209–214 (1982).
6. Steffen, D. Proviruses are adjacent to *c-myc* in some murine leukemia virus-induced lymphomas. *Proc. Natl Acad. Sci. USA* **81**, 2097–2101 (1984).
7. Peters, G. Oncogenes at viral integration sites. *Cell Growth Differ.* **1**, 503–510 (1990).
8. Shen-Ong, G. L., Keath, E. J., Piccoli, S. P. & Cole, M. D. Novel *myc* oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas. *Cell* **31**, 443–452 (1982).
9. Crews, S., Barth, R., Hood, L., Prehn, J. & Calame, K. Mouse *c-myc* oncogene is located on chromosome 15 and translocated to chromosome 12 in plasmacytomas. *Science* **218**, 1319–1321 (1982).
10. Dalla-Favera, R. *et al.* Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. *Proc. Natl Acad. Sci. USA* **79**, 7824–7827 (1982).
11. Neel, B. G., Jhanwar, S. C., Chaganti, R. S. & Hayward, W. S. Two human *c-onc* genes are located on the long arm of chromosome 8. *Proc. Natl Acad. Sci. USA* **79**, 7842–7846 (1982).
12. Taub, R. *et al.* Translocation of the *c-myc* gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. *Proc. Natl Acad. Sci. USA* **79**, 7837–7841 (1982).
13. de Klein, A. *et al.* A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. *Nature* **300**, 765–767 (1982).
14. Adams, J. M. *et al.* The *c-myc* oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. *Nature* **318**, 533–538 (1985).
15. Boxer, L. M. & Dang, C. V. Translocations involving *c-myc* and *c-myc* function. *Oncogene* **20**, 5595–5610 (2001).
16. Alitalo, K., Schwab, M., Lin, C. C., Varmus, H. E. & Bishop, J. M. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (*c-myc*) in malignant neuroendocrine cells from a human colon carcinoma. *Proc. Natl Acad. Sci. USA* **80**, 1707–1711 (1983).
17. Dalla-Favera, R., Wong-Staal, F. & Gallo, R. C. *Onc* gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. *Nature* **299**, 61–63 (1982).
18. Collins, S. & Groudine, M. Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line. *Nature* **298**, 679–681 (1982).
19. Schwab, M. *et al.* Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. *Nature* **305**, 245–248 (1983).
20. Kohl, N. E. *et al.* Transposition and amplification of oncogene-related sequences in human neuroblastomas. *Cell* **35**, 359–367 (1983).
21. Schwab, M. *et al.* Enhanced expression of the human gene *N-myc* consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. *Proc. Natl Acad. Sci. USA* **81**, 4940–4944 (1984).
22. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E. & Bishop, J. M. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. *Science* **224**, 1121–1124 (1984).
23. Zimmerman, K. & Alt, F. W. Expression and function of *myc* family genes. *Crit. Rev. Oncog.* **2**, 75–95 (1990).
24. Nau, M. M. *et al. L-myc*, a new *myc*-related gene amplified and expressed in human small cell lung cancer. *Nature* **318**, 69–73 (1985).
25. Zajac-Kaye, M. *Myc* oncogene: a key component in cell cycle regulation and its implication for lung cancer. *Lung Cancer* **34** (Suppl. 2), S43–S46 (2001).
26. Wu, R. *et al.* Amplification and overexpression of the *L-MYC* proto-oncogene in ovarian carcinomas. *Am. J. Pathol.* **162**, 1603–1610 (2003).
27. Abrams, H. D., Rohrschneider, L. R. & Eisenman, R. N. Nuclear location of the putative transforming protein of avian myelocytomatosis virus. *Cell* **29**, 427–439 (1982).
28. Donner, P., Greiser-Wilke, I. & Moelling, K. Nuclear localization and DNA binding of the transforming gene product of avian myelocytomatosis virus. *Nature* **296**, 262–269 (1982).
29. Hann, S. R., Abrams, H. D., Rohrschneider, L. R. & Eisenman, R. N. Proteins encoded by *v-myc* and *c-myc* oncogenes: identification and localization in acute leukemia virus transformants and bursal lymphoma cell lines. *Cell* **34**, 789–798 (1983).
30. Kelly, K., Cochran, B. H., Stiles, C. D. & Leder, P. Cell-specific regulation of the *c-myc* gene by lymphocyte mitogens and platelet-derived growth factor. *Cell* **35**, 603–610 (1983).
31. Dani, C. *et al.* Extreme instability of *myc* mRNA in normal and transformed human cells. *Proc. Natl Acad. Sci. USA* **81**, 7046–7050 (1984).
32. Hann, S. R. & Eisenman, R. N. Proteins encoded by the human *c-myc* oncogene: differential expression in neoplastic cells. *Mol. Cell. Biol.* **4**, 2486–2497 (1984).
33. Hann, S. R., Thompson, C. B. & Eisenman, R. N. *c-myc* oncogene protein synthesis is independent of the cell cycle in human and avian cells. *Nature* **314**, 366–369 (1985).
34. Thompson, C. B., Challoner, P. B., Neiman, P. E. & Groudine, M. Levels of *c-myc* oncogene mRNA are invariant throughout the cell cycle. *Nature* **314**, 363–366 (1985).
35. Lachman, H. M. & Skoultchi, A. I. Expression of *c-myc* changes during differentiation of mouse erythroleukaemia cells. *Nature* **310**, 592–594 (1984).
36. Gonda, T. J. & Metcalf, D. Expression of *myb*, *myc* and *fos* proto-oncogenes during the differentiation of a murine myeloid leukaemia. *Nature* **310**, 249–251 (1984).
37. Campisi, J., Gray, H. E., Pardee, A. B., Dean, M. & Sonenshein, G. E. Cell-cycle control of *c-myc* but *not c-ras* expression is lost following chemical transformation. *Cell* **36**, 241–247 (1984).
38. Dean, M. *et al.* Regulation of *c-myc* transcription and mRNA abundance by serum growth factors and cell contact. *J. Biol. Chem.* **261**, 9161–9166 (1986).
39. Marcu, K. B., Bossone, S. A. & Patel, A. J. *myc* function and regulation. *Annu. Rev. Biochem.* **61**, 809–860 (1992).
40. Spencer, C. A. & Groudine, M. Control of *c-myc* regulation in normal and neoplastic cells. *Adv. Cancer Res.* **56**, 1–48 (1991).
41. Battey, J. *et al.* The human *c-myc* oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. *Cell* **34**, 779–787 (1983).

42. Watt, R. *et al.* The structure and nucleotide sequence of the 5′ end of the human *c-myc* oncogene. *Proc. Natl Acad. Sci. USA* **80**, 6307–6311 (1983).
43. Bentley, D. L. & Groudine, M. A block to elongation is largely responsible for decreased transcription of *c-myc* in differentiated HL60 cells. *Nature* **321**, 702–706 (1986).
44. Nepveu, A. & Marcu, K. B. Intragenic pausing and anti-sense transcription within the murine *c-myc* locus. *EMBO J.* **5**, 2859–2865 (1986).
45. Nepveu, A., Marcu, K. B., Skoultchi, A. I. & Lachman, H. M. Contributions of transcriptional and post-transcriptional mechanisms to the regulation of *c-myc* expression in mouse erythroleukemia cells. *Genes Dev.* **1**, 938–945 (1987).
46. Siebenlist, U., Hennighausen, L., Battey, J. & Leder, P. Chromatin structure and protein binding in the putative regulatory region of the *c-myc* gene in Burkitt lymphoma. *Cell* **37**, 381–391 (1984).
47. Dyson, P. J., Littlewood, T. D., Forster, A. & Rabbitts, T. H. Chromatin structure of transcriptionally active and inactive human *c-myc* alleles. *EMBO J.* **4**, 2885–2891 (1985).
48. Chung, H. J. & Levens, D. *c-myc* expression: keep the noise down! *Mol. Cells* **20**, 157–166 (2005).
49. Levens, D. How the *c-myc* promoter works and why it sometimes does not. *J. Natl Cancer Inst. Monogr.*, 41–43 (2008).
50. Bentley, D. L. & Groudine, M. Sequence requirements for premature termination of transcription in the human *c-myc* gene. *Cell* **53**, 245–256 (1988).
51. Eick, D. & Bornkamm, G. W. Transcriptional arrest within the first exon is a fast control mechanism in *c-myc* gene expression. *Nucleic Acids Res.* **14**, 8331–8346 (1986).
52. Wierstra, I. & Alves, J. The *c-myc* promoter: still MysterY and Challenge. *Adv. Cancer Res.* **99**, 113–333 (2008).
53. Cheng, A. S. *et al.* Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-α responsive promoters. *Mol. Cell* **21**, 393–404 (2006).
54. Afar, D. E., Goga, A., McLaughlin, J., Witte, O. N. & Sawyers, C. L. Differential complementation of *Bcr–Abl* point mutants with *c-Myc*. *Science* **264**, 424–426 (1994).
55. He, T. C. *et al.* Identification of c-MYC as a target of the APC pathway. *Science* **281**, 1509–1512 (1998).
56. Oster, S. K., Ho, C. S., Soucie, E. L. & Penn, L. Z. The *myc* oncogene: MarvelouslY Complex. *Adv. Cancer Res.* **84**, 81–154 (2002).
57. Roussel, M. F., Cleveland, J. L., Shurtleff, S. A. & Sherr, C. J. *Myc* rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. *Nature* **353**, 361–363 (1991).
58. Barone, M. V. & Courtneidge, S. A. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. *Nature* **378**, 509–512 (1995).
59. Weng, A. P. *et al. c-Myc* is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/ lymphoma. *Genes Dev.* **20**, 2096–2109 (2006).
60. Kouzine, F. & Levens, D. Supercoil-driven DNA structures regulate genetic transactions. *Front. Biosci.* **12**, 4409–4423 (2007).
61. Blanchard, J. M. *et al. c-myc* gene is transcribed at high rate in G_0-arrested fibroblasts and is post-transcriptionally regulated in response to growth factors. *Nature* **317**, 443–445 (1985).
62. Ross, J. mRNA stability in mammalian cells. *Microbiol. Rev.* **59**, 423–450 (1995).
63. Jones, T. R. & Cole, M. D. Rapid cytoplasmic turnover of *c-myc* mRNA: requirement of the 3′ untranslated sequences. *Mol. Cell. Biol.* **7**, 4513–4521 (1987).
64. Brewer, G. & Ross, J. Poly(A) shortening and degradation of the 3′ A + U-rich sequences of human c-myc mRNA in a cell-free system. *Mol. Cell. Biol.* **8**, 1697–1708 (1988).
65. Bernstein, P. L., Herrick, D. J., Prokipcak, R. D. & Ross, J. Control of *c-myc* mRNA half-life *in vitro* by a protein capable of binding to a coding region stability determinant. *Genes Dev.* **6**, 642–654 (1992).
66. Leder, A., Pattengale, P. K., Kuo, A., Stewart, T. A. & Leder, P. Consequences of widespread deregulation of the *c-myc* gene in transgenic mice: multiple neoplasms and normal development. *Cell* **45**, 485–495 (1986).
67. Cole, M. D. The *myc* oncogene: its role in transformation and differentiation. *Annu. Rev. Genet.* **20**, 361–384 (1986).
68. Littlewood, T. D. & Evan, G. I. The role of myc oncogenes in cell growth and differentiation. *Adv. Dent. Res.* **4**, 69–79 (1990).
69. Hann, S. R., King, M. W., Bentley, D. L., Anderson, C. W. & Eisenman, R. N. A non-AUG translational initiation in *c-myc* exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas. *Cell* **52**, 185–195 (1988).
70. Facchini, L. M. & Penn, L. Z. The molecular role of *Myc* in growth and transformation: recent discoveries lead to new insights. *FASEB J.* **12**, 633–651 (1998).
71. Hann, S. R. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. *Semin. Cancer Biol.* **16**, 288–302 (2006).
72. Vervoorts, J., Luscher-Firzlaff, J. & Luscher, B. The ins and outs of MYC regulation by posttranslational mechanisms. *J. Biol. Chem.* **281**, 34725–34729 (2006).
73. Welcker, M. & Clurman, B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. *Nature Rev. Cancer* **8**, 83–93 (2008).
74. Sears, R. C. The life cycle of C-myc: from synthesis to degradation. *Cell Cycle* **3**, 1133–1137 (2004).
75. Arnold, H. K. & Sears, R. C. A tumor suppressor role for PP2A-B56α through negative regulation of c-Myc and other key oncoproteins. *Cancer Metastasis Rev.* **27**, 147–158 (2008).
76. Spotts, G. D., Patel, S. V., Xiao, Q. & Hann, S. R. Identification of downstream-initiated c-Myc proteins which are dominant-negative inhibitors of transactivation by full-length c-Myc proteins. *Mol. Cell. Biol.* **17**, 1459–1468 (1997).
77. Cobbold, L. C. *et al.* Identification of internal ribosome entry segment (IRES)-*trans*-acting factors for the Myc family of IRESs. *Mol. Cell. Biol.* **28**, 40–49 (2008).
78. Land, H., Parada, L. F. & Weinberg, R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. *Nature* **304**, 596–602 (1983).
79. Ruley, H. E. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. *Nature* **304**, 602–606 (1983).
80. Vaux, D. L., Cory, S. & Adams, J. M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with *c-myc* to immortalize pre-B cells. *Nature* **335**, 440–442 (1988).
81. Strasser, A., Harris, A. W., Bath, M. L. & Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between *myc* and *bcl-2*. *Nature* **348**, 331–333 (1990).
82. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. *Cell* **100**, 57–70 (2000).
83. Bild, A. H. *et al.* Oncogenic pathway signatures in human cancers as a guide to targeted therapies. *Nature* **439**, 353–357 (2006).
84. Armelin, H. A. *et al.* Functional role for c-myc in mitogenic response to platelet-derived growth factor. *Nature* **310**, 655–660 (1984).
85. Gusse, M., Ghysdael, J., Evan, G., Soussi, T. & Mechali, M. Translocation of a store of maternal cytoplasmic c-myc protein into nuclei during early development. *Mol. Cell. Biol.* **9**, 5395–5403 (1989).
86. Gutierrez, C. *et al.* Is c-myc protein directly involved in DNA replication? *Science* **240**, 1202–1203 (1988).
87. Pierce, S. B. *et al.* dMyc is required for larval growth and endoreplication in *Drosophila*. *Development* **131**, 2317–2327 (2004).
88. Maines, J. Z., Stevens, L. M., Tong, X. & Stein, D. *Drosophila* dMyc is required for ovary cell growth and endoreplication. *Development* **131**, 775–786 (2004).
89. Dominguez-Sola, D. *et al.* Non-transcriptional control of DNA replication by c-Myc. *Nature* **448**, 445–451 (2007).
90. Luscher, B. & Eisenman, R. N. New light on Myc and Myb. Part I. Myc. *Genes Dev.* **4**, 2025–2035 (1990).
91. Kingston, R. E., Baldwin, A. S. Jr & Sharp, P. A. Regulation of heat shock protein 70 gene expression by c-myc. *Nature* **312**, 280–282 (1984).
92. Landschulz, W. H., Johnson, P. F. & McKnight, S. L. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. *Science* **240**, 1759–1764 (1988).
93. Murre, C., McCaw, P. S. & Baltimore, D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. *Cell* **56**, 777–783 (1989).
94. Dang, C. V., McGuire, M., Buckmire, M. & Lee, W. M. Involvement of the 'leucine zipper' region in the oligomerization and transforming activity of human c-myc protein. *Nature* **337**, 664–666 (1989).
95. Stone, J. *et al.* Definition of regions in human c-myc that are involved in transformation and nuclear localization. *Mol. Cell. Biol.* **7**, 1697–1709 (1987).
96. Kato, G. J., Barrett, J., Villa-Garcia, M. & Dang, C. V. An amino-terminal c-myc domain required for neoplastic transformation activates transcription. *Mol. Cell. Biol.* **10**, 5914–5920 (1990).
97. Blackwell, T. K., Kretzner, L., Blackwood, E. M., Eisenman, R. N. & Weintraub, H. Sequence-specific DNA binding by the c-Myc protein. *Science* **250**, 1149–1151 (1990).
98. Prendergast, G. C. & Ziff, E. B. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. *Science* **251**, 186–189 (1991).
99. Blackwood, E. M. & Eisenman, R. N. Max: a helix–loop–helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. *Science* **251**, 1211–1217 (1991).
100. Amati, B. *et al.* Oncogenic activity of the c-Myc protein requires dimerization with Max. *Cell* **72**, 233–245 (1993).
101. Ayer, D. E., Kretzner, L. & Eisenman, R. N. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. *Cell* **72**, 211–222 (1993).
102. Rottmann, S. & Luscher, B. The Mad side of the Max network: antagonizing the function of Myc and more. *Curr. Top. Microbiol. Immunol.* **302**, 63–122 (2006).
103. Nair, S. K. & Burley, S. K. Structural aspects of interactions within the Myc/Max/Mad network. *Curr. Top. Microbiol. Immunol.* **302**, 123–143 (2006).
104. Billin, A. N. & Ayer, D. E. The Mlx network: evidence for a parallel Max-like transcriptional network that regulates energy metabolism. *Curr. Top. Microbiol. Immunol.* **302**, 255–278 (2006).
105. Wahlstrom, T. & Henriksson, M. Mnt takes control as key regulator of the myc/max/mxd network. *Adv. Cancer Res.* **97**, 61–80 (2007).
106. McMahon, S. B., Van Buskirk, H. A., Dugan, K. A., Copeland, T. D. & Cole, M. D. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. *Cell* **94**, 363–374 (1998).
107. McMahon, S. B., Wood, M. A. & Cole, M. D. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. *Mol. Cell. Biol.* **20**, 556–562 (2000).
108. Cheng, S. W. *et al.* c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. *Nature Genet.* **22**, 102–105 (1999).
109. Knoepfler, P. S. *et al.* Myc influences global chromatin structure. *EMBO J.* **25**, 2723–2734 (2006).
110. Eberhardy, S. R. & Farnham, P. J. c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. *J. Biol. Chem.* **276**, 48562–48571 (2001).
111. Eberhardy, S. R. & Farnham, P. J. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. *J. Biol. Chem.* **277**, 40156–40162 (2002).
112. Cowling, V. H. & Cole, M. D. The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. *Mol. Cell. Biol.* **27**, 2059–2073 (2007).
113. Cowling, V. H. & Cole, M. D. Mechanism of transcriptional activation by the Myc oncoproteins. *Semin. Cancer Biol.* **16**, 242–252 (2006).
114. Amati, B., Frank, S. R., Donjerkovic, D. & Taubert, S. Function of the c-Myc oncoprotein in chromatin remodeling and transcription. *Biochim. Biophys. Acta* **1471**, M135–M145 (2001).
115. Adhikary, S. & Eilers, M. Transcriptional regulation and transformation by Myc proteins. *Nature Rev. Mol. Cell. Biol.* **6**, 635–645 (2005).
116. Cleveland, J. L. *et al.* Negative regulation of c-myc transcription involves myc family proteins. *Oncogene Res.* **3**, 357–375 (1988).
117. Penn, L. J., Brooks, M. W., Laufer, E. M. & Land, H. Negative autoregulation of c-myc transcription. *EMBO J.* **9**, 1113–1121 (1990).
118. Penn, L. J. *et al.* Domains of human c-myc protein required for autosuppression and cooperation with *ras* oncogenes are overlapping. *Mol. Cell. Biol.* **10**, 4961–4966 (1990).
119. Grignani, F. *et al.* Negative autoregulation of *c-myc* gene expression is inactivated in transformed cells. *EMBO J.* **9**, 3913–3922 (1990).
120. Xiao, Q. *et al.* Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis. *Genes Dev.* **12**, 3803–3808 (1998).

121. Lee, L. A., Dolde, C., Barrett, J., Wu, C. S. & Dang, C. V. A link between c-Myc-mediated transcriptional repression and neoplastic transformation. *J. Clin. Invest.* **97**, 1687–1695 (1996).
122. Li, L. H., Nerlov, C., Prendergast, G., MacGregor, D. & Ziff, E. B. c-Myc represses transcription *in vivo* by a novel mechanism dependent on the initiator element and Myc box II. *EMBO J.* **13**, 4070–4079 (1994).
123. Mao, D. Y. *et al.* Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. *Curr. Biol.* **13**, 882–886 (2003).
124. Kleine-Kohlbrecher, D., Adhikary, S. & Eilers, M. Mechanisms of transcriptional repression by Myc. *Curr. Top. Microbiol. Immunol.* **302**, 51–62 (2006).
125. Adhikary, S. *et al.* The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. *Cell* **123**, 409–421 (2005).
126. Mao, D. Y. *et al.* Promoter-binding and repression of PDGFRB by c-Myc are separable activities. *Nucleic Acids Res.* **32**, 3462–3468 (2004).
127. Eilers, M., Picard, D., Yamamoto, K. R. & Bishop, J. M. Chimaeras of myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells. *Nature* **340**, 66–68 (1989).
128. Eilers, M., Schirm, S. & Bishop, J. M. The MYC protein activates transcription of the alpha-prothymosin gene. *EMBO J.* **10**, 133–141 (1991).
129. Wagner, A. J., Meyers, C., Laimins, L. A. & Hay, N. c-Myc induces the expression and activity of ornithine decarboxylase. *Cell Growth Differ.* **4**, 879–883 (1993).
130. Bello-Fernandez, C., Packham, G. & Cleveland, J. L. The ornithine decarboxylase gene is a transcriptional target of c-Myc. *Proc. Natl Acad. Sci. USA* **90**, 7804–7808 (1993).
131. Littlewood, T. D., Hancock, D. C., Danielian, P. S., Parker, M. G. & Evan, G. I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. *Nucleic Acids Res.* **23**, 1686–1690 (1995).
132. Picard, D. Posttranslational regulation of proteins by fusions to steroid-binding domains. *Methods Enzymol.* **327**, 385–401 (2000).
133. Mateyak, M. K., Obaya, A. J., Adachi, S. & Sedivy, J. M. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. *Cell Growth Differ.* **8**, 1039–1048 (1997).
134. Bush, A. *et al. c-myc* null cells misregulate *cad* and *gadd45* but not other proposed c-Myc targets. *Genes Dev.* **12**, 3797–3802 (1998).
135. Marhin, W. W., Chen, S., Facchini, L. M., Fornace, A. J. Jr & Penn, L. Z. Myc represses the growth arrest gene *gadd45*. *Oncogene* **14**, 2825–2834 (1997).
136. Miltenberger, R. J., Sukow, K. A. & Farnham, P. J. An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. *Mol. Cell. Biol.* **15**, 2527–2535 (1995).
137. Watson, J. D., Oster, S. K., Shago, M., Khosravi, F. & Penn, L. Z. Identifying genes regulated in a Myc-dependent manner. *J. Biol. Chem.* **277**, 36921–36930 (2002).
138. Dang, C. V. *et al.* The c-Myc target gene network. *Semin. Cancer Biol.* **16**, 253–264 (2006).
139. Zeller, K. I., Jegga, A. G., Aronow, B. J., O'Donnell, K. A. & Dang, C. V. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. *Genome Biol.* **4**, R69 (2003).
140. Barsyte-Lovejoy, D. *et al.* The *c-Myc* oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. *Cancer Res.* **66**, 5330–5337 (2006).
141. Guccione, E. *et al.* Myc-binding-site recognition in the human genome is determined by chromatin context. *Nature Cell Biol.* **8**, 764–770 (2006).
142. Zeller, K. I. *et al.* Global mapping of c-Myc binding sites and target gene networks in human B cells. *Proc. Natl Acad. Sci. USA* **103**, 17834–17839 (2006).
143. Patel, J. H., Loboda, A. P., Showe, M. K., Showe, L. C. & McMahon, S. B. Analysis of genomic targets reveals complex functions of MYC. *Nature Rev. Cancer* **4**, 562–568 (2004).
144. Chen, X. *et al.* Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. *Cell* **133**, 1106–1117 (2008).
145. Levens, D. L. Reconstructing MYC. *Genes Dev.* **17**, 1071–1077 (2003).
146. Arabi, A. *et al.* c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. *Nature Cell Biol.* **7**, 303–310 (2005).
147. Grandori, C. *et al.* c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. *Nature Cell Biol.* **7**, 311–318 (2005).
148. Gomez-Roman, N., Grandori, C., Eisenman, R. N. & White, R. J. Direct activation of RNA polymerase III transcription by c-Myc. *Nature* **421**, 290–294 (2003).
149. Grewal, S. S., Li, L., Orian, A., Eisenman, R. N. & Edgar, B. A. Myc-dependent regulation of ribosomal RNA synthesis during *Drosophila* development. *Nature Cell Biol.* **7**, 295–302 (2005).
150. Dang, C. V., Kim, J. W., Gao, P. & Yustein, J. The interplay between MYC and HIF in cancer. *Nature Rev. Cancer* **8**, 51–56 (2008).
151. O'Donnell, K. A., Wentzel, E. A., Zeller, K. I., Dang, C. V. & Mendell, J. T. c-Myc-regulated microRNAs modulate E2F1 expression. *Nature* **435**, 839–843 (2005).
152. He, L. *et al.* A microRNA polycistron as a potential human oncogene. *Nature* **435**, 828–833 (2005).
153. Lee, L. A. & Dang, C. V. Myc target transcriptomes. *Curr. Top. Microbiol. Immunol.* **302**, 145–167 (2006).
154. de la Cova, C. & Johnston, L. A. Myc in model organisms: a view from the flyroom. *Semin. Cancer Biol.* **16**, 303–312 (2006).
155. de Alboran, I. M. *et al.* Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. *Immunity* **14**, 45–55 (2001).
156. Trumpp, A. *et al.* c-Myc regulates mammalian body size by controlling cell number but not cell size. *Nature* **414**, 768–773 (2001).
157. Obaya, A. J., Mateyak, M. K. & Sedivy, J. M. Mysterious liaisons: the relationship between c-Myc and the cell cycle. *Oncogene* **18**, 2934–2941 (1999).
158. Langdon, W. Y., Harris, A. W., Cory, S. & Adams, J. M. The *c-myc* oncogene perturbs B lymphocyte development in *Eμ-myc* transgenic mice. *Cell* **47**, 11–18 (1986).
159. Coppola, J. A. & Cole, M. D. Constitutive *c-myc* oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment. *Nature* **320**, 760–763 (1986).
160. Gandarillas, A. & Watt, F. M. c-Myc promotes differentiation of human epidermal stem cells. *Genes Dev.* **11**, 2869–2882 (1997).
161. Prochownik, E. V. & Kukowska, J. Deregulated expression of *c-myc* by murine erythroleukaemia cells prevents differentiation. *Nature* **322**, 848–850 (1986).
162. Dmitrovsky, E. *et al.* Expression of a transfected human *c-myc* oncogene inhibits differentiation of a mouse erythroleukaemia cell line. *Nature* **322**, 748–750 (1986).
163. Pirity, M., Blanck, J. K. & Schreiber-Agus, N. Lessons learned from Myc/Max/Mad knockout mice. *Curr. Top. Microbiol. Immunol.* **302**, 205–234 (2006).
164. Hurlin, P. J. & Huang, J. The MAX-interacting transcription factor network. *Semin. Cancer Biol.* **16**, 265–274 (2006).
165. Grandori, C., Cowley, S. M., James, L. P. & Eisenman, R. N. The Myc/Max/Mad network and the transcriptional control of cell behavior. *Annu. Rev. Cell Dev. Biol.* **16**, 653–699 (2000).
166. Luscher, B. & Larsson, L. G. The basic region/helix-loop-helix/leucine zipper domain of Myc proto-oncoproteins: function and regulation. *Oncogene* **18**, 2955–2966 (1999).
167. Baudino, T. A. & Cleveland, J. L. The Max network gone mad. *Mol. Cell. Biol.* **21**, 691–702 (2001).
168. *Wilson*, A. *et al.* c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. *Genes Dev.* **18**, 2747–2763 (2004).
169. Baudino, T. A. *et al.* c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. *Genes Dev.* **16**, 2530–2543 (2002).
170. Bellmeyer, A., Krase, J., Lindgren, J. & LaBonne, C. The protooncogene *c-myc* is an essential regulator of neural crest formation in xenopus. *Dev. Cell* **4**, 827–839 (2003).
171. Knoepfler, P. S., Cheng, P. F. & Eisenman, R. N. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. *Genes Dev.* **16**, 2699–2712 (2002).
172. Schuhmacher, M. *et al.* Control of cell growth by c-Myc in the absence of cell division. *Curr. Biol.* **9**, 1255–1258 (1999).
173. Iritani, B. M. & Eisenman, R. N. c-Myc enhances protein synthesis and cell size during B lymphocyte development. *Proc. Natl Acad. Sci. USA* **96**, 13180–13185 (1999).
174. Dang, C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. *Mol. Cell. Biol.* **19**, 1–11 (1999).
175. Schmidt, E. V. The role of c-myc in regulation of translation initiation. *Oncogene* **23**, 3217–3221 (2004).
176. Mai, S., Fluri, M., Siwarski, D. & Huppi, K. Genomic instability in MycER-activated Rat1A-MycER cells. *Chromosome Res.* **4**, 365–371 (1996).
177. Mai, S., Hanley-Hyde, J. & Fluri, M. c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. *Oncogene* **12**, 277–288 (1996).
178. Li, Q. & Dang, C. V. c-Myc overexpression uncouples DNA replication from mitosis. *Mol. Cell. Biol.* **19**, 5339–5351 (1999).
179. Felsher, D. W. & Bishop, J. M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. *Proc. Natl Acad. Sci. USA* **96**, 3940–3944 (1999).
180. Yin, X. Y., Grove, L., Datta, N. S., Long, M. W. & Prochownik, E. V. C-myc overexpression and p53 loss cooperate to promote genomic instability. *Oncogene* **18**, 1177–1184 (1999).
181. Prochownik, E. V. & Li, Y. The ever expanding role for c-Myc in promoting genomic instability. *Cell Cycle* **6**, 1024–1029 (2007).
182. Soucek, L. & Evan, G. *Myc* — Is this the oncogene from Hell? *Cancer Cell* **1**, 406–408 (2002).
183. Wade, M. & Wahl, G. M. c-Myc, genome instability, and tumorigenesis: the devil is in the details. *Curr. Top. Microbiol. Immunol.* **302**, 169–203 (2006).
184. Dang, C. V., Li, F. & Lee, L. A. Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability? *Cell Cycle* **4**, 1465–1466 (2005).
185. Louis, S. F. *et al.* c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus. *Proc. Natl Acad. Sci. USA* **102**, 9613–9618 (2005).
186. Qi, Y. *et al.* $p19^{ARF}$ directly and differentially controls the functions of c-Myc independently of p53. *Nature* **431**, 712–717 (2004).
187. Prochownik, E. V. Functional and physical communication between oncoproteins and tumor suppressors. *Cell. Mol. Life Sci.* **62**, 2438–2459 (2005).
188. Gorrini, C. *et al.* Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. *Nature* **448**, 1063–1067 (2007).
189. Adachi, S. *et al.* c-Myc is necessary for DNA damage-induced apoptosis in the G_2 phase of the cell cycle. *Mol. Cell. Biol.* **21**, 4929–4937 (2001).
190. Reimann, M. *et al.* The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas *in vivo*. *Blood* **110**, 2996–3004 (2007).
191. Ngo, C. V. *et al.* An *in vivo* function for the transforming Myc protein: elicitation of the angiogenic phenotype. *Cell Growth Differ.* **11**, 201–210 (2000).
192. Dews, M. *et al.* Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. *Nature Genet.* **38**, 1060–1065 (2006).
193. Watnick, R. S., Cheng, Y. N., Rangarajan, A., Ince, T. A. & Weinberg, R. A. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. *Cancer Cell* **3**, 219–231 (2003).
194. Pelengaris, S., Khan, M. & Evan, G. I. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. *Cell* **109**, 321–334 (2002).
195. Pelengaris, S., Littlewood, T., Khan, M., Elia, G. & Evan, G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. *Mol. Cell* **3**, 565–577 (1999).
196. Pelengaris, S., Khan, M. & Evan, G. *c-MYC*: more than just a matter of life and death. *Nature Rev. Cancer* **2**, 764–776 (2002).
197. Soucek, L. *et al.* Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. *Nature Med.* **13**, 1211–1218 (2007).
198. Shi, Y. *et al.* Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. *Science* **257**, 212–214 (1992).

199. Evan, G. I. *et al.* Induction of apoptosis in fibroblasts by c-myc protein. *Cell* **69**, 119–128 (1992).
200. Askew, D. S., Ashmun, R. A., Simmons, B. C. & Cleveland, J. L. Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. *Oncogene* **6**, 1915–1922 (1991).
201. Harrington, E. A., Bennett, M. R., Fanidi, A. & Evan, G. I. c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. *EMBO J.* **13**, 3286–3295 (1994).
202. Meyer, N., Kim, S. S. & Penn, L. Z. The Oscar-worthy role of Myc in apoptosis. *Semin. Cancer Biol.* **16**, 275–287 (2006).
203. Fanidi, A., Harrington, E. A. & Evan, G. I. Cooperative interaction between *c-myc* and *bcl-2* proto-oncogenes. *Nature* **359**, 554–556 (1992).
204. Bissonnette, R. P., Echeverri, F., Mahboubi, A. & Green, D. R. Apoptotic cell death induced by *c-myc* is inhibited by *bcl-2*. *Nature* **359**, 552–554 (1992).
205. Soucie, E. L. *et al.* Myc potentiates apoptosis by stimulating Bax activity at the mitochondria. *Mol. Cell. Biol.* **21**, 4725–4736 (2001).
206. de Alboran, I. M., Baena, E. & Martinez, A. C. *c-Myc*-deficient B lymphocytes are resistant to spontaneous and induced cell death. *Cell Death Differ.* **11**, 61–68 (2004).
207. Dang, C. V., O'Donnell, K., A. & Juopperi, T. The great MYC escape in tumorigenesis. *Cancer Cell* **8**, 177–178 (2005).
208. Nieminen, A. I., Partanen, J. I. & Klefstrom, J. c-Myc blazing a trail of death: coupling of the mitochondrial and death receptor apoptosis pathways by c-Myc. *Cell Cycle* **6**, 2464–2472 (2007).
209. Hermeking, H. & Eick, D. Mediation of c-Myc-induced apoptosis by p53. *Science* **265**, 2091–2093 (1994).
210. Wagner, A. J., Kokontis, J. M. & Hay, N. Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce $p21^{waf1/cip1}$. *Genes Dev.* **8**, 2817–2830 (1994).
211. Zindy, F. *et al.* Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. *Genes Dev.* **12**, 2424–2433 (1998).
212. Herold, S. *et al.* Negative regulation of the mammalian UV response by Myc through association with Miz-1. *Mol. Cell* **10**, 509–521 (2002).
213. Staller, P. *et al.* Repression of p15INK4b expression by Myc through association with Miz-1. *Nature Cell Biol.* **3**, 392–399 (2001).
214. Gartel, A. L. *et al.* Myc represses the $p21^{WAF1/CIP1}$ promoter and interacts with Sp1/Sp3. *Proc. Natl Acad. Sci. USA* **98**, 4510–4515 (2001).
215. Seoane, J., Le, H. V. & Massague, J. Myc suppression of the $p21^{Cip1}$ Cdk inhibitor influences the outcome of the p53 response to DNA damage. *Nature* **419**, 729–734 (2002).
216. Finch, A. *et al.* Bcl-x_L gain of function and p19 ARF loss of function cooperate oncogenically with Myc *in vivo* by distinct mechanisms. *Cancer Cell* **10**, 113–120 (2006).
217. Eischen, C. M., Weber, J. D., Roussel, M. F., Sherr, C. J. & Cleveland, J. L. Disruption of the ARF–Mdm2–p53 tumor suppressor pathway in Myc-induced lymphomagenesis. *Genes Dev.* **13**, 2658–2669 (1999).
218. Schmitt, C. A., McCurrach, M. E., de Stanchina, E., Wallace-Brodeur, R. R. & Lowe, S. W. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. *Genes Dev.* **13**, 2670–2677 (1999).
219. Bouchard, C. *et al.* FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. *Genes Dev.* **21**, 2775–2787 (2007).
220. Alt, J. R., Greiner, T. C., Cleveland, J. L. & Eischen, C. M. *Mdm2* haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. *EMBO J.* **22**, 1442–1450 (2003).
221. Jacobs, J. J. *et al.* Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. *Genes Dev.* **13**, 2678–2690 (1999).
222. Dickins, R. A. *et al.* Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. *Nature Genet.* **37**, 1289–1295 (2005).
223. Kim, S. S. *et al.* CUL7 is a novel antiapoptotic oncogene. *Cancer Res.* **67**, 9616–9622 (2007).
224. Maestro, R. *et al. Twist* is a potential oncogene that inhibits apoptosis. *Genes Dev.* **13**, 2207–2217 (1999).
225. van Lohuizen, M. *et al.* Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging. *Cell* **65**, 737–752 (1991).
226. Eischen, C. M. *et al.* Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. *Oncogene* **20**, 6983–6993 (2001).
227. Eischen, C. M., Woo, D., Roussel, M. F. & Cleveland, J. L. Apoptosis triggered by Myc-induced suppression of Bcl-X_L or Bcl-2 is bypassed during lymphomagenesis. *Mol. Cell. Biol.* **21**, 5063–5070 (2001).
228. Maclean, K. H., Keller, U. B., Rodriguez-Galindo, C., Nilsson, J. A. & Cleveland, J. L. c-Myc augments γ irradiation-induced apoptosis by suppressing Bcl-X_L. *Mol. Cell. Biol.* **23**, 7256–7270 (2003).
229. Dansen, T. B., Whitfield, J., Rostker, F., Brown-Swigart, L. & Evan, G. I. Specific requirement for Bax, not Bak, in Myc-induced apoptosis and tumor suppression *in vivo*. *J. Biol. Chem.* **281**, 10890–10895 (2006).
230. Juin, P. *et al.* c-Myc functionally cooperates with Bax to induce apoptosis. *Mol. Cell. Biol.* **22**, 6158–6169 (2002).
231. Annis, M. G. *et al.* Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. *EMBO J.* **24**, 2096–2103 (2005).
232. Eischen, C. M., Roussel, M. F., Korsmeyer, S. J. & Cleveland, J. L. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis. *Mol. Cell. Biol.* **21**, 7653–7662 (2001).
233. Sakamuro, D. *et al.* c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. *Oncogene* **11**, 2411–2418 (1995).
234. Egle, A., Harris, A. W., Bouillet, P. & Cory, S. Bim is a suppressor of Myc-induced mouse B cell leukemia. *Proc. Natl Acad. Sci. USA* **101**, 6164–6169 (2004).
235. Hemann, M. T. *et al.* Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. *Nature* **436**, 807–811 (2005).
236. Goga, A., Yang, D., Tward, A. D., Morgan, D. O. & Bishop, J. M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. *Nature Med.* **13**, 820–827 (2007).
237. Schreiber-Agus, N. *et al. Drosophila* Myc is oncogenic in mammalian cells and plays a role in the *diminutive* phenotype. *Proc. Natl Acad. Sci. USA* **94**, 1235–1240 (1997).
238. Gallant, P., Shiio, Y., Cheng, P. F., Parkhurst, S. M. & Eisenman, R. N. Myc and Max homologs in *Drosophila*. *Science* **274**, 1523–1527 (1996).
239. Gallant, P. Myc/Max/Mad in invertebrates: the evolution of the Max network. *Curr. Top. Microbiol. Immunol.* **302**, 235–253 (2006).
240. Gallant, P. Myc, cell competition, and compensatory proliferation. *Cancer Res.* **65**, 6485–6487 (2005).
241. Davis, A. C., Wims, M., Spotts, G. D., Hann, S. R. & Bradley, A. A null *c-myc* mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. *Genes Dev.* **7**, 671–682 (1993).
242. Bettess, M. D. *et al.* c-Myc is required for the formation of intestinal crypts but dispensable for homeostasis of the adult intestinal epithelium. *Mol. Cell. Biol.* **25**, 7868–7878 (2005).
243. Oskarsson, T. *et al.* Skin epidermis lacking the *c-Myc* gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the $p21^{Cip1}$ gene. *Genes Dev.* **20**, 2024–2029 (2006).
244. Zhong, W. *et al.* Hypertrophic growth in cardiac myocytes is mediated by Myc through a Cyclin D2-dependent pathway. *EMBO J.* **25**, 3869–3879 (2006).
245. Martins, R. A. *et al.* N-myc coordinates retinal growth with eye size during mouse development. *Genes Dev.* **22**, 179–193 (2008).
246. Zindy, F. *et al.* N-Myc and the cyclin-dependent kinase inhibitors $p18^{Ink4c}$ and $p27^{Kip1}$ coordinately regulate cerebellar development. *Proc. Natl Acad. Sci. USA* **103**, 11579–11583 (2006).
247. Zindy, F. *et al.* Genetic alterations in mouse medulloblastomas and generation of tumors *de novo* from primary cerebellar granule neuron precursors. *Cancer Res.* **67**, 2676–2684 (2007).
248. Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. *Mol. Cell* **4**, 199–207 (1999).
249. Arvanitis, C. & Felsher, D. W. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. *Semin. Cancer Biol.* **16**, 313–317 (2006).
250. Pelengaris, S. & Khan, M. The many faces of c-MYC. *Arch. Biochem. Biophys.* **416**, 129–136 (2003).
251. Jain, M. *et al.* Sustained loss of a neoplastic phenotype by brief inactivation of *MYC*. *Science* **297**, 102–104 (2002).
252. Boxer, R. B., Jang, J. W., Sintasath, L. & Chodosh, L. A. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. *Cancer Cell* **6**, 577–586 (2004).
253. D'Cruz, C. M. *et al.* c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous *Kras2* mutations. *Nature Med.* **7**, 235–239 (2001).
254. Tran, T. P. *et al.* Combined inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. *PLOS ONE* **3**, e2125 (2008).
255. Podsypanina, K., Politi, K., Beverly, L. J. & Varmus, H. E. Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by *Myc* and mutant *Kras*. *Proc. Natl Acad. Sci. USA* **105**, 5242–5247 (2008).
256. Luscher, B. & Larsson, L. G. The world according to, MYC. Conference on MYC and the transcriptional control of proliferation and oncogenesis. *EMBO Rep.* **8**, 1110–1114 (2007).
257. Cole, M. D. & Henriksson, M. 25 years of the *c-Myc* oncogene. *Semin. Cancer Biol.* **16**, 241 (2006).
258. Ellwood-Yen, K. *et al.* Myc-driven murine prostate cancer shares molecular features with human prostate tumors. *Cancer Cell* **4**, 223–238 (2003).
259. Lossos, I. S. *et al.* Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. *Proc. Natl Acad. Sci. USA* **99**, 8886–8891 (2002).
260. Adler, A. S. *et al.* Genetic regulators of large-scale transcriptional signatures in cancer. *Nature Genet.* **38**, 421–430 (2006).
261. Vita, M. & Henriksson, M. The Myc oncoprotein as a therapeutic target for human cancer. *Semin. Cancer Biol.* **16**, 318–330 (2006).
262. Ponzielli, R., Katz, S., Barsyte-Lovejoy, D. & Penn, L. Z. Cancer therapeutics: targeting the dark side of Myc. *Eur. J. Cancer* **41**, 2485–2501 (2005).
263. Hurley, L. H., Von Hoff, D. D., Siddiqui-Jain, A. & Yang, D. Drug targeting of the *c-MYC* promoter to repress gene expression via a G-quadruplex silencer element. *Semin. Oncol.* **33**, 498–512 (2006).
264. Trumpp, A. & Wiestler, O. D. Mechanisms of disease: cancer stem cells — targeting the evil twin. *Nature Clin. Pract. Oncol.* **5**, 337–347 (2008).
265. Robson, S., Pelengaris, S. & Khan, M. c-Myc and downstream targets in the pathogenesis and treatment of cancer. *Recent Patents Anticancer Drug Discov.* **1**, 305–326 (2006).
266. Prochownik, E. V. c-Myc as a therapeutic target in cancer. *Expert Rev. Anticancer Ther.* **4**, 289–302 (2004).
267. Fernandez, P. C. *et al.* Genomic targets of the human c-Myc protein. *Genes Dev.* **17**, 1115–1129 (2003).
268. Watt, F. M., Frye, M. & Benitah, S. A. *MYC* in mammalian epidermis: how can an oncoge ne stimulate differentiation? *Nature Rev. Cancer* **8**, 234–242 (2008).
269. Varmus, H. E. The molecular genetics of cellular oncogenes. *Annu. Rev. Genet.* **18**, 553–612 (1984).
270. Johnston, L. A., Prober, D. A., Edgar, B. A., Eisenman, R. N. & Gallant, P. *Drosophila* myc regulates cellular growth during development. *Cell* **98**, 779–790 (1999).
271. Orian, A. *et al.* Genomic binding by the *Drosophila* Myc, Max, Mad/Mnt transcription factor network. *Genes Dev.* **17**, 1101–1114 (2003).
272. Goodliffe, J. M., Wieschaus, E. & Cole, M. D. Polycomb mediates Myc autorepression and its transcriptional control of many loci in *Drosophila*. *Genes Dev.* **19**, 2941–2946 (2005).
273. Loo, L. W. *et al.* The transcriptional repressor dMnt is a regulator of growth in *Drosophila melanogaster*. *Mol. Cell. Biol.* **25**, 7078–7091 (2005).
274. Secombe, J., Li, L., Carlos, L. & Eisenman, R. N. The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. *Genes Dev.* **21**, 537–551 (2007).
275. de la Cova, C., Abril, M., Bellosta, P., Gallant, P. & Johnston, L. A. *Drosophila* myc regulates organ size by inducing cell competition. *Cell* **117**, 107–116 (2004).
276. Moreno, E. & Basler, K. dMyc transforms cells into super-competitors. *Cell* **117**, 117–129 (2004).
277. Knoepfler, P. S. Why *myc*? An unexpected ingredient in the stem cell cocktail. *Cell Stem Cell* **2**, 18–21 (2008).

278. Cartwright, P. *et al.* LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. *Development* **132**, 885–896 (2005).
279. Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-competent induced pluripotent stem cells. *Nature* **448**, 313–317 (2007).
280. Wernig, M. *et al. In vitro* reprogramming of fibroblasts into a pluripotent ES-cell-like state. *Nature* **448**, 318–324 (2007).
281. Nakagawa, M. *et al.* Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. *Nature Biotechnol.* **26**, 101–106 (2008).
282. Li, Z. *et al.* A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. *Proc. Natl Acad. Sci. USA* **100**, 8164–8169 (2003).
283. Shachaf, C. M. *et al.* MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. *Nature* **431**, 1112–1117 (2004).
284. Wong, D. J. *et al.* Module map of stem cell genes guides creation of epithelial cancer stem cells. *Cell Stem Cell* **2**, 333–344 (2008).
285. Ben-Porath, I. *et al.* An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nature Genet.* **40**, 499–507 (2008).
286. Wu, C. H. *et al.* Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. *PLOS Genet.* **4**, e1000090 (2008).
287. Zhang, X. Y. *et al.* The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression. *Mol. Cell* **29**, 102–111 (2008).
288. Malynn, B. A. *et al.* N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. *Genes Dev.* **14**, 1390–1399 (2000).
289. Liu, J., Martin, H. J., Liao, G. & Hayward, S. D. The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. *J. Virol.* **81**, 10451–10459 (2007).
290. Bajaj, B. G. *et al.* Epstein–Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. *J. Virol.* **82**, 4082–4090 (2008).
291. Stewart, T. A., Pattengale, P. K. & Leder, P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. *Cell* **38**, 627–637 (1984).
292. Schoenenberger, C. A. *et al.* Targeted *c-myc* gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. *EMBO J.* **7**, 169–175 (1988).
293. Flores, I., Murphy, D. J., Swigart, L. B., Knies, U. & Evan, G. I. Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. *Oncogene* **23**, 5923–5930 (2004).

Acknowledgements
We thank our MYC colleagues who share our passion for, or perhaps it is our addiction to, solving the MYC puzzle. Without you there would be no progress or story to tell. Obviously, there are so many important contributions, big and small, that could not be cited here owing to space and reference constraints. We particularly thank our colleagues who took the time to review and discuss this article with us, including M. Cole, C. Dang, B. Luscher and B. Neel, as well as our anonymous reviewers who provided additionalguidance. The funding agencies that enable our research include the Ontario Institute for Cancer Research network through funding provided by the Province of Ontario, the National Cancer Institute of Canada with funds from the Canadian Cancer Society, the Canadian Institute for Health Research, the Department of Defense Breast Cancer Research Program and the Canadian Breast Cancer Research Alliance.

DATABASES

Entrez Gene:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene
ABL1 | *BCL2* | *Bcl2l11* | *BCR* | *GADD45A* | *H19* | *HRAS1* | *MYC* | *MYCL1* | *MYCN* | *ODC1* | *PTMA*
National Cancer Institute Drug Dictionary:
http://www.cancer.gov/drugdictionary/4-hydroxytamoxifen
OMIM: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM
Burkitt lymphoma
UniProtKB: http://www.uniprot.org
ARF | BAX | BCL-X$_L$ | BMI1 | CDC25A | CDK4 | CUL7 | cyclin A2 | cyclin D1 | cyclin D2 | cyclin E1 | E2F1 | E2F2 | FBW7 | HRAS | INI1 | LIF | MAX | MDM2 | MIZ1 | MNT | MYC | p21 | p53 | SP1 | TRRAP | TWIST1 | USP22

FURTHER INFORMATION

Linda Z. Penn's homepage: http://www.pennlab.ca
MYC Cancer Gene: http://www.myc-cancer-gene.org

ALL LINKS ARE ACTIVE IN THE ONLINE PDF